Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07-23 20:40:12时区推断·⟳ 抓取 07-23 20:42:15·⚡ 决策 07-24 08:05:10 +11h22m·95.5 天前
Quest Diagnostics二季度EPS和收入超预期并上调全年指引
公司Q2调整后EPS为3.12美元，高于一致预期2.82美元，收入30.4亿美元高于29.7亿美元。
📄 原文Investing.com↗ 原文
Why is Quest Diagnostics stock surging today?
Google raises annual spending estimates amid rapid AI infrastructure build-out Investing.com -- Quest Diagnostics stock…
不做 Quest Diagnostics（DGX.US）
财报利好已在盘前和当日交易中兑现，当前不追。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 high · price-in 风险 high ↗
消息传播链
- 报道Q2业绩超预期、全年指引上调及盘前上涨7.3%。市场反应:Futu显示DGX.US 2026-07-23收盘较前收上涨约5.97%。
关键理由
- 公司Q2调整后EPS为3.12美元，高于一致预期2.82美元，收入30.4亿美元高于29.7亿美元。
- 全年2026收入指引上调至119.5亿至120.5亿美元，调整后EPS指引上调至11.05至11.25美元。
主要风险
- 信号到达后美股已完成当日交易，Quest Diagnostics当日收涨约5.97%，盘前利好已被市场消化。
反向证据
- 做多前查反向 · 来源 stock_quote · 日期 2026-07-23 · 影响 weakens
当日已大幅高开并收涨，短线追多edge不足。
检索:DGX.US stock_quote earnings reaction
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,053 字
Google raises annual spending estimates amid rapid AI infrastructure build-out
Investing.com -- Quest Diagnostics stock surged 7.3% in pre-open trading after the company reported second-quarter 2026 adjusted earnings per share of $3.12, handily topping the Wall Street consensus of $2.82, while quarterly revenue of $3.04 billion came in ahead of the $2.97 billion analysts had forecast — representing year-over-year revenue growth of 10.2%. The strong results, released before the market opened, were accompanied by a meaningful lift to full-year 2026 guidance, with the company now targeting revenue of $11.95–$12.05 billion and adjusted EPS of $11.05–$11.25, both above prior consensus estimates.
The earnings beat extended Quest’s track record of topping Wall Street expectations, having surpassed bottom-line estimates in each of the prior four quarterly reporting periods. Following the results, Jefferies raised its price target on the shares to $225 from $220 while maintaining a Buy rating, citing the beat on both sales and earnings as justification for the higher valuation. The analyst action added further momentum to the pre-market move.
The broader U.S. equity market provided a challenging backdrop, with the S&P 500 down 0.8%, the Dow Jones Industrial Average off 0.85%, and the Nasdaq declining 1.2%, underscoring that today’s move in Quest Diagnostics is entirely attributable to company-specific catalysts rather than any tailwind from the wider market. The stock’s pre-market price of $225.09 also pushed it above its prior 52-week high of $219.20, marking a fresh multi-year peak.
Taken together, an outsized earnings surprise, a raised full-year outlook, and a supportive analyst price target upgrade created a powerful convergence of catalysts that drove Quest Diagnostics sharply higher even as the rest of the market retreated, reinforcing the company’s reputation as a consistent executor in the diagnostics sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Investing.com -- Quest Diagnostics stock surged 7.3% in pre-open trading after the company reported second-quarter 2026 adjusted earnings per share of $3.12, handily topping the Wall Street consensus of $2.82, while quarterly revenue of $3.04 billion came in ahead of the $2.97 billion analysts had forecast — representing year-over-year revenue growth of 10.2%. The strong results, released before the market opened, were accompanied by a meaningful lift to full-year 2026 guidance, with the company now targeting revenue of $11.95–$12.05 billion and adjusted EPS of $11.05–$11.25, both above prior consensus estimates.
The earnings beat extended Quest’s track record of topping Wall Street expectations, having surpassed bottom-line estimates in each of the prior four quarterly reporting periods. Following the results, Jefferies raised its price target on the shares to $225 from $220 while maintaining a Buy rating, citing the beat on both sales and earnings as justification for the higher valuation. The analyst action added further momentum to the pre-market move.
The broader U.S. equity market provided a challenging backdrop, with the S&P 500 down 0.8%, the Dow Jones Industrial Average off 0.85%, and the Nasdaq declining 1.2%, underscoring that today’s move in Quest Diagnostics is entirely attributable to company-specific catalysts rather than any tailwind from the wider market. The stock’s pre-market price of $225.09 also pushed it above its prior 52-week high of $219.20, marking a fresh multi-year peak.
Taken together, an outsized earnings surprise, a raised full-year outlook, and a supportive analyst price target upgrade created a powerful convergence of catalysts that drove Quest Diagnostics sharply higher even as the rest of the market retreated, reinforcing the company’s reputation as a consistent executor in the diagnostics sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。